Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesResidual cardiovascular risk in treated hypertension and hyperlipidaemia: The PRIME Study
Journal of Human Hypertension, 06/03/09
Blacher J et al. – Treatment with antihypertensive agents, but not with lipid-lowering agents, was associated with a sizeable residual cardiovascular risk, suggesting that more efficient risk reduction strategies in hypertension should be developed as a priority.
Methods- Study of the degree of cardiovascular risk remaining in hypertension and dyslipidaemia pts treated pharmacologically
- Assessment of levels of risk factors achieved that is 'residual cardiovascular risk'
- Use of data from the Prospective Epidemiological Study of Myocardial Infarction (PRIME)
- PRIME subjects: 9649 men age 50–59 yrs, from France and Northern Ireland with 10-yr follow-up
- PRIME tested presence of specific residual cardiovascular risks of coronary heart disease, stroke, total of fatal and non-fatal cardiovascular events and cardiovascular mortality, in pts treated with antihypertensive agents or lipid-lowering agents
- In whole cohort, 796 pts developed fatal or non-fatal cardiovascular event
- Antihypertensive drug use at baseline significantly associated with total cardiovascular event risk, but not lipid-lowering drug use, after adjusting for classic risk factors
- Adjusted classic risk factors: age, smoking, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure and diabetes
- Similar results for coronary heart disease, stroke, and cardiovascular death, but neither for total death nor for non-cardiovascular death
- For any cardiovascular endpoint, residual risks did not globally differ by antihypertensive drug class prescribed at baseline
Today in Atherosclerosis/Lipids...keeping you current
Receive free subspecialty "5-minute updates" via email
Smoking intensity and lipoprotein abnormalities in active smokers
Journal of Clinical Lipidology, 12/18/09
Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia
Current Medical Research and Opinion, 12/18/09
Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
Lipids in Health and Disease, 12/18/09
Today in Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Improved 24-Hour Blood Pressure Control With Sirolimus Versus Calcineurin Inhibitor Based Immunosuppression in Renal Transplant Recipients
Transplantation Proceedings, 12/18/09
Zigzagged Augmentation Index in Diabetes
Clinical and Experimental Hypertension, 12/18/09
Scleroderma Renal Crisis: A Rare but Severe Complication of Systemic Sclerosis
Clinical Reviews in Allergy and Immunology, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor